Our lead candidate, somavaratan (VRS-317), is a novel, long-acting form of recombinant human growth hormone in late-stage clinical trials for the treatment of GHD in children and adults. Somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance and, therefore, treatment outcomes.

Novel Technology
Somavaratan is powered by the novel XTEN® technology that is designed to prolong its treatment effect to allow twice-monthly dosing, with the goal of improving treatment adherence and outcomes.
Our Pipeline
Versartis’ research and development efforts are focused on orphan endocrine diseases for which improved treatment approaches are needed.

Commitment to Patients

Clinical trials are central to our research and development efforts to deliver innovative treatments for endocrine diseases to patients who can benefit from the improved therapies. Our current clinical trial efforts are focused on developing somavaratan, a twice-monthly, long-acting form of growth hormone for children and adults with GHD.

If you’re looking for a global company that embraces the environment of a small, fast-paced biotech where you are encouraged to speak up and challenge assumptions, we invite you to learn more about career opportunities at Versartis.